000134863 001__ 134863
000134863 005__ 20240229105045.0
000134863 0247_ $$2doi$$a10.1093/neuonc/nox216
000134863 0247_ $$2pmid$$apmid:29165638
000134863 0247_ $$2pmc$$apmc:PMC5961072
000134863 0247_ $$2ISSN$$a1522-8517
000134863 0247_ $$2ISSN$$a1523-5866
000134863 0247_ $$2altmetric$$aaltmetric:29096945
000134863 037__ $$aDKFZ-2018-00653
000134863 041__ $$aeng
000134863 082__ $$a610
000134863 1001_ $$0P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aPfaff, Elke$$b0$$eFirst author
000134863 245__ $$aFeasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.
000134863 260__ $$aOxford$$bOxford Univ. Press$$c2018
000134863 3367_ $$2DRIVER$$aarticle
000134863 3367_ $$2DataCite$$aOutput Types/Journal article
000134863 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660116200_9237
000134863 3367_ $$2BibTeX$$aARTICLE
000134863 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000134863 3367_ $$00$$2EndNote$$aJournal Article
000134863 500__ $$aPfaff E*, Kessler T*  (*first author") / David T. W. Jones,# Wolfgang Wick,# and Felix Sahm# last authors
000134863 520__ $$aO6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma patients. Glioblastoma without hypermethylated MGMT promoter is largely resistant to treatment with temozolomide. These patients are in particular need of new treatment approaches, which are offered by biomarker-driven clinical trials with targeted drugs based on molecular characterization of individual tumors.In preparation for an upcoming clinical study, a comprehensive molecular profiling approach was undertaken on tissues from 43 glioblastoma patients harboring an unmethylated MGMT promoter at diagnosis. The diagnostic pipeline covered various levels of molecular characteristics, including whole-exome sequencing, low-coverage whole-genome sequencing, RNA sequencing, as well as microarray-based gene expression profiling and DNA methylation arrays.Complex multilayer molecular diagnostics were feasible in this setting with a median turnaround time of 4-5 weeks from surgery to the molecular tumor board. In 35% of cases, potentially relevant therapeutic decisions were derived from the data. Alterations were most frequently found in receptor tyrosine kinases, members of the phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin and mitogen-activated protein kinase pathway as well as cell cycle control and p53 regulation cascades. Individual tumors harbored clonal alterations such as oncogenic fusions of tyrosine kinases which constitute promising targets for targeted therapies. A prioritization algorithm is proposed to allocate patients with multiple targets to the potentially best treatment option.With this feasibility study, a comprehensive molecular profiling approach for patients with newly diagnosed glioblastoma harboring an unmethylated MGMT promoter is presented. Analyses in this pilot cohort serve as a basis for trials based on targetable alterations and on the question of allocation of patients to the best treatment arm.
000134863 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000134863 588__ $$aDataset connected to CrossRef, PubMed,
000134863 7001_ $$0P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aKessler, Tobias$$b1$$eFirst author
000134863 7001_ $$0P:(DE-HGF)0$$aBalasubramanian, Gnana Prakash$$b2
000134863 7001_ $$0P:(DE-HGF)0$$aBerberich, Anne$$b3
000134863 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b4
000134863 7001_ $$0P:(DE-HGF)0$$aWick, Antje$$b5
000134863 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b6
000134863 7001_ $$aUnterberg, Andreas$$b7
000134863 7001_ $$aBendszus, Martin$$b8
000134863 7001_ $$aHerold-Mende, Christel$$b9
000134863 7001_ $$aCapper, David$$b10
000134863 7001_ $$0P:(DE-HGF)0$$aSchenkel, Irini$$b11
000134863 7001_ $$0P:(DE-He78)cef2261a4b41e6c8b36045623e0a025d$$aEisenmenger, Andreas$$b12
000134863 7001_ $$0P:(DE-He78)8b508b91c472089d47f0930c895fd342$$aDettmer, Susan$$b13
000134863 7001_ $$0P:(DE-He78)fc949170377b58098e46141d95c72661$$aBrors, Benedikt$$b14
000134863 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b15
000134863 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b16
000134863 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b17
000134863 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b18$$eLast author
000134863 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b19$$eLast author
000134863 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b20$$eLast author
000134863 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nox216$$gVol. 20, no. 6, p. 826 - 837$$n6$$p826 - 837$$tNeuro-Oncology$$v20$$x1523-5866$$y2018
000134863 909CO $$ooai:inrepo02.dkfz.de:134863$$pVDB
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cef2261a4b41e6c8b36045623e0a025d$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8b508b91c472089d47f0930c895fd342$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fc949170377b58098e46141d95c72661$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000134863 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000134863 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000134863 9141_ $$y2018
000134863 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000134863 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000134863 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000134863 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000134863 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000134863 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000134863 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000134863 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000134863 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000134863 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000134863 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000134863 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000134863 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000134863 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x2
000134863 9201_ $$0I:(DE-He78)G200-20160331$$kG200$$lAngewandte Bioinformatik$$x3
000134863 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x4
000134863 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x5
000134863 9201_ $$0I:(DE-He78)G040-20160331$$kG040$$lKlinische Studienzentrale$$x6
000134863 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x7
000134863 980__ $$ajournal
000134863 980__ $$aVDB
000134863 980__ $$aI:(DE-He78)B062-20160331
000134863 980__ $$aI:(DE-He78)L101-20160331
000134863 980__ $$aI:(DE-He78)G370-20160331
000134863 980__ $$aI:(DE-He78)G200-20160331
000134863 980__ $$aI:(DE-He78)G380-20160331
000134863 980__ $$aI:(DE-He78)E050-20160331
000134863 980__ $$aI:(DE-He78)G040-20160331
000134863 980__ $$aI:(DE-He78)G160-20160331
000134863 980__ $$aUNRESTRICTED